About Kim Rockley

Kim Rockley, PhD. Kim holds a PhD in Pharmacy from Durham University where she studied anthracycline-induced cardiotoxicity and its mitigation by in vitro. Before this, Kim gained with a BSc in Biomedical Science and a Master’s degree in Cancer Pharmacology from the University of Bradford, graduating with distinction. She also has experience as a Clinical Trial Coordinator at the Haematology and Oncology Centre, University Hospitals Bristol NHS foundation Trust. Kim is a creative research scientist who enjoys the busy and dynamic environment of ApconiX.

Safety Pharmacology Society (SPS) Annual Meeting 2021

Join Dr Kimberley Rockley for a Session on Seizure Liability Safety Pharmacology Society Annual Meeting 2021: SPS 2021 Virtual Annual Meeting will take place between the 4th and 8th of October. "Seizure Liability" Session On the 5th October at 10am Eastern Daylight Time, as part of the seizure liability [...]

By |2021-09-23T16:42:32+01:00September 23rd, 2021|Events|Comments Off on Safety Pharmacology Society (SPS) Annual Meeting 2021

ApconiX Begins Seizure Liability Research Using Axion Biosystems Maestro Edge Microelectrode Array (MEA) System

ApconiX Begins Seizure Liability Research Using Axion Biosystems Maestro Edge Multielectrode Array (MEA) System We were thrilled to welcome Katherine Czysz from FUJIFILM Cellular Dynamics to assist with seeding co-cultures of iPS-derived neuronal cells for our initial MEA study. Human glutamatergic-enriched cortical neurons derived from iPS cells (iCell GlutaNeurons) were seeded [...]

By |2021-09-08T16:44:18+01:00July 22nd, 2021|Company News|Comments Off on ApconiX Begins Seizure Liability Research Using Axion Biosystems Maestro Edge Microelectrode Array (MEA) System

Seizure Toxicology Research Paper Published

Seizure Toxicology Research Paper Published Introduction: Detection of neurotoxicity induced by prospective new therapies represents a major challenge due to the morphological and physiological complexity of the central nervous system (CNS). Characterised by uncontrolled electrical activity in the brain, seizure liability remains a significant cause of attrition in drug [...]

By |2021-08-12T15:22:01+01:00January 22nd, 2020|Publications|Comments Off on Seizure Toxicology Research Paper Published

Alleviating the Long-term Cardiotoxicity of Cancer Therapies

Alleviating the Long-term Cardiotoxicity of Cancer Therapies Kimberly Rockley completed her PhD in the Division of Pharmacy at Durham University before joining us at ApconiX in June last year. Her research utilised in vitro cardiomyocyte models to investigate the link between angiotensin signalling and anthracycline-induced cardiotoxicity. Here she describes [...]

By |2021-08-12T15:39:04+01:00January 16th, 2020|Toxicology|Comments Off on Alleviating the Long-term Cardiotoxicity of Cancer Therapies

Innovative Models for In Vitro Detection of Seizure

Innovative Models for In Vitro Detection of Seizure ApconiX is delighted that Dr Kim Rockley's article ‘ Innovative models for in vitro detection of seizure‘ has now been accepted for publication in Toxicology Research. The article highlights how new technologies such as microelectrode array and ion channel screening offer [...]

By |2021-09-15T16:07:54+01:00November 20th, 2019|Publications, Ion Channels|Comments Off on Innovative Models for In Vitro Detection of Seizure

ApconiX Conduct Pilot Study with Axion Biosystems

ApconiX Conduct Pilot Study with Axion Biosystems We were thrilled to welcome Jayne Ingram from Axion Biosystems into the ApconiX laboratory to conduct a pilot study using their Maestro Pro microelectrode array (MEA) system and Ncardia iPSC-derived neuronal cells.  The cells were cultured for three weeks before Jayne arrived [...]

By |2021-09-08T16:57:57+01:00October 10th, 2019|Ion Channels, Toxicology|Comments Off on ApconiX Conduct Pilot Study with Axion Biosystems